Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period

European Journal of Endocrinology

Volumn 160, Issue 1, 2009, Pages 53-58

  Padidela, Raja ^a,b   Patterson, Michael ^c   Sharief, Nawfal ^d   Ghatei, Mohammed ^c   Hussain, Khalid ^a,b,e  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d BASILDON HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 (7 36)AMIDE; GLUCAGON LIKE PEPTIDE 1 (9 36) AMIDE; GLUCAGON-LIKE PEPTIDE 1 (7-36)AMIDE; GLUCAGON-LIKE PEPTIDE-1 (9-36)-AMIDE; PEPTIDE; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL MILK; BIRTH WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE FUNCTION; ENDOCRINE SYSTEM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOREACTIVITY; INFANT; INSULIN BLOOD LEVEL; MALE; MULTICENTER STUDY; NEWBORN; PANCREAS ISLET BETA CELL; PERINATAL DEVELOPMENT; POSTPRANDIAL STATE; PREMATURITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSED PHASE LIQUID CHROMATOGRAPHY; TISSUE REGENERATION; ADULT; BLOOD; METABOLISM; PROSPECTIVE STUDY;

ADULT; BLOOD GLUCOSE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INSULIN; MALE; PEPTIDE FRAGMENTS; PEPTIDES; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 58249092363     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0807     Document Type: Article

References (32)

1. Eissele R, Goke R, Willemer S, Harthus HP, Vermeer H, Arnold R & Goke B. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. European Journal of Clinical Investigation 1992 22 283-291.
2. Orskov C, Holst JJ, Poulsen SS & Kirkegaard P. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 1987 30 874-881.
3. Mojsov S, Kopczynski MG & Habener JF. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. Journal of Biological Chemistry 1990 265 8001-8008.
4. Orskov C, Rabenhoj L, Wettergren A, Kofod H & Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994 43 535-539.
5. Kieffer TJ, McIntosh CH & Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995 136 3585-3596.
6. Vilsboll T, Krarup T, Deacon CF, Madsbad S & Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001 50 609-613.
7. Muscelli E, Mari A, Natali A, Astiarraga BD, Camastra S, Frascerra S, Holst JJ & Ferrannini E. Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance. American Journal of Physiology. Endocrinology and Metabolism 2006 291 E1144-E1150.
8. Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, Gastaldelli A, Holst JJ & Ferrannini E. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008 57 1340-1348.
9. Drucker DJ. The biology of incretin hormones. Cell Metabolism 2006 3 153-165.
10. Brubaker PL & Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004 145 2653-2659.
11. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Molecular Endocrinology 2003 17 161-171.
12. Xu G, Stoffers DA, Habener JF & Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999 48 2270-2276.
13. Bouwens L & Rooman I. Regulation of pancreatic beta-cell mass. Physiological Reviews 2005 85 1255-1270.
14. Kaung HL. Growth dynamics of pancreatic islet cell populations during fetal and neonatal development of the rat. Developmental Dynamics 1994 200 163-175.
15. Kreymann B, Williams G, Ghatei MA & Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987 2 1300-1304.
16. Wood WG, Wachter C & Scriba PC. Experiences using chloramine-T and 1, 3, 4, 6-tetrachloro-3 alpha, 6 alpha-diphenylglycoluril (Iodogen) for radioiodination of materials for radioimmunoassay. Journal of Clinical Chemistry and Clinical Biochemistry 1981 19 1051-1056.
17. Patterson M, Murphy KG, le Roux CW, Ghatei MA & Bloom SR. Characterization of ghrelin-like immunoreactivity in human plasma. Journal of Clinical Endocrinology and Metabolism 2005 90 2205-2211.
18. Amin H, Holst JJ, Hartmann B, Wallace L, Wright J & Sigalet DL. Functional ontogeny of the proglucagon-derived peptide axis in the premature human neonate. Pediatrics 2008 121 e180-e186.
19. Lucas A, Bloom SR & Ynsley-Green A. Postnatal surges in plasma gut hormones in term and preterm infants. Biology of the Neonate 1982 41 63-67.
20. Lucas A, Sarson DL, Bloom SR & Ynsley-Green A. Developmental aspects of gastric inhibitory polypeptide (GIP) and its possible role in the enteroinsular axis in neonates. Acta Paediatrica Scandinavica 1980 69 321-325.
21. Schou JH, Pilgaard K, Vilsboll T, Jensen CB, Deacon CF, Holst JJ, Volund A, Madsbad S & Vaag AA. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight. Journal of Clinical Endocrinology and Metabolism 2005 90 4912-4919.
22. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG & Holst JJ. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2003 88 2706-2713.
23. Ruiz-Grande C, Pintado J, Alarcon C, Castilla C, Valverde I & Lopez-Novoa JM. Renal catabolism of human glucagon-like peptides 1 and 2. Canadian Journal of Physiology and Pharmacology 1990 68 1568-1573.
24. Aperia A, Broberger O, Elinder G, Herin P & Zetterstrom R. Postnatal development of renal function in pre-term and full-term infants. Acta Paediatrica Scandinavica 1981 70 183-187.
25. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE & Gallwitz B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004 53 654-662.
26. Dai H, Gustavson SM, Preston GM, Eskra JD, Calle R & Hirshberg B. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. Diabetes, Obesity and Metabolism 2008 10 506-513.
27. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG & Bloom SR. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Annals of Surgery 2006 243 108-114.
28. Morinigo R, Moize V, Musri M, Lacy AM, Navarro S, Marin JL, Delgado S, Casamitjana R & Vidal J. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. Journal of Clinical Endocrinology and Metabolism 2006 91 1735-1740.
29. Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J, Hanto DW, Callery M, Arky R, Nose V, Bonner-Weir S & Goldfine AB. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005 48 2236-2240.
30. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML & Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. New England Journal of Medicine 2005 353 249-254.
31. Ahren B. Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes. Drug Discovery Today. Therapeutic Strategies 2004 1 207-212.
32. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J & Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996 37 969-972.